Provided by Lei Li
Lei Li is the Managing Partner of Sidley's Shanghai and Beijing offices. He advises clients on a broad range of regulatory, compliance and government enforcement matters in China, with a particular focus on the life sciences industry. He is the co-head of Sidley’s nationally leading China Life Sciences practice.
Lei Li has extensive experience in all types of anti-corruption compliance and investigation matters in China. Representing both multinational companies and local Chinese companies, he has handled a large number of government anti-corruption inquiries and investigations, including those conducted by the U.S. regulators under the U.S. Foreign Corrupt Practices Act (FCPA), and those conducted by Chinese administrative enforcement authorities and criminal prosecution authorities. He also has worked extensively on internal anti-corruption risk assessments, audits and investigations, and anti-corruption due diligence reviews in M&A transactions.
Lei Li is an experienced antitrust lawyer, and has practiced antitrust law in China since the passage of China’s Anti-monopoly Law in 2008. He has focused his antitrust practice on regulatory compliance, internal investigations and government investigations. He has handled over a dozen of high-stake antitrust inquiries and investigations launched by the central and provincial antitrust authorities in China, primarily in the pharmaceutical and medical device sector.